PMID

Data

Article Title

Organization

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Boehringer Ingelheim Rcv

Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

Glaxosmithkline

Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Cellzome

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.

Glaxosmithkline

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Roche Palo Alto

Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

National Center For Advancing Translational Sciences